Cancer Research

Minnow and Mighty Titan Collaborate

evotec-Bilderberg-Thomas Ernsting
I wonder what happens if I press this.
  • Why it matters

    Why it matters

    The planned alliance between major Sanofi and Evotec will enable the two companies to combine their staff and substance libraries, as well as their efforts to develop new cancer drugs.

  • Facts

    Facts

    • Evotec will take over a Sanofi facility in Toulouse, along with 200 Sanofi employees there.
    • Sanofi will guarantee at least €250 million in payments to Evotec within the next five years.
    • The two companies will combine their data collections by bundling Sanofi’s 1.3 million substances with the 400,000 molecules in Evotec’s substance library.
  • Audio

    Audio

  • Pdf

Evotec and Sanofi confirmed on Tuesday plans to collaborate in exploring and developing new cancer drugs over a five-year period. The companies aim to sign an agreement early next year.

The alliance would be one of the biggest between a German biotech company and established pharmaceutical firm.

Evotec and Sanofi, Europe’s third-largest pharmaceutical company with €33 billion ($41 billion) in annual sales, plan to combine their cancer research efforts in a number of concrete projects.

In addition to providing services in preclinical research for the pharmaceutical company, Evotec will take on more than 200 Sanofi employees in Toulouse, where it will establish a new site. The company currently employs more than 600 scientists.

As part of the joint venture, Sanofi will guarantee at least €250 million in payments to Evotec over a five-year period and outsource a portion of its early product development activities.

Want to keep reading?

Subscribe now or log in to read our coverage of Europe’s leading economy.